R T Dorr

2.5k total citations
59 papers, 1.9k citations indexed

About

R T Dorr is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, R T Dorr has authored 59 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Organic Chemistry and 13 papers in Oncology. Recurrent topics in R T Dorr's work include Cancer therapeutics and mechanisms (10 papers), Bioactive Compounds and Antitumor Agents (6 papers) and Cancer Treatment and Pharmacology (6 papers). R T Dorr is often cited by papers focused on Cancer therapeutics and mechanisms (10 papers), Bioactive Compounds and Antitumor Agents (6 papers) and Cancer Treatment and Pharmacology (6 papers). R T Dorr collaborates with scholars based in United States, Germany and United Kingdom. R T Dorr's co-authors include David S. Alberts, William S. Dalton, David S. Alberts, Yan Cai, Fazal Imam Shahi, James A. Crowell, C S Yang, H.‐H. Sherry Chow, Iman A. Hakim and Yukihiko Hara and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Medicinal Chemistry.

In The Last Decade

R T Dorr

58 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R T Dorr United States	23	727	502	328	326	191	59	1.9k
Daniel W. Nixon United States	27	697 1.0×	978 1.9×	144 0.4×	69 0.2×	267 1.4×	86	3.1k
Kateřina Dvořáková United States	17	332 0.5×	569 1.1×	173 0.5×	99 0.3×	176 0.9×	31	1.5k
David Mitchell United States	24	916 1.3×	1000 2.0×	410 1.3×	29 0.1×	210 1.1×	81	2.6k
Masahiro Iwaki Japan	22	378 0.5×	435 0.9×	45 0.1×	334 1.0×	60 0.3×	141	1.9k
Tomohiro Yano Japan	28	330 0.5×	1.4k 2.7×	190 0.6×	38 0.1×	106 0.6×	169	2.7k
Nehad M. Ayoub Jordan	26	351 0.5×	603 1.2×	162 0.5×	51 0.2×	79 0.4×	72	1.7k
Jean‐Louis Beaudeux France	28	209 0.3×	883 1.8×	163 0.5×	33 0.1×	438 2.3×	91	2.8k
Yali Ren China	23	194 0.3×	669 1.3×	141 0.4×	52 0.2×	234 1.2×	70	2.1k
Françoise Stanke‐Labesque France	26	130 0.2×	400 0.8×	167 0.5×	54 0.2×	368 1.9×	123	2.3k
Pankaj B. Desai United States	29	657 0.9×	715 1.4×	982 3.0×	20 0.1×	143 0.7×	81	3.1k

Countries citing papers authored by R T Dorr

Since Specialization

Citations

This map shows the geographic impact of R T Dorr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R T Dorr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R T Dorr more than expected).

Fields of papers citing papers by R T Dorr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R T Dorr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R T Dorr. The network helps show where R T Dorr may publish in the future.

Co-authorship network of co-authors of R T Dorr

This figure shows the co-authorship network connecting the top 25 collaborators of R T Dorr. A scholar is included among the top collaborators of R T Dorr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R T Dorr. R T Dorr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Remers, William A. & R T Dorr. (2012). Chemistry and Pharmacology of Imexon and Related Cyanoaziridines. Current Medicinal Chemistry. 19(33). 5745–5753. 5 indexed citations

Baker, Amanda F. & R T Dorr. (2001). Drug interactions with the taxanes: clinical implications. Cancer Treatment Reviews. 27(4). 221–233. 37 indexed citations

Chow, H.‐H. Sherry, Yan Cai, David S. Alberts, et al.. (2001). Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.. PubMed. 10(1). 53–8. 338 indexed citations

López, Ana Mariá, et al.. (1999). Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemotherapy and Pharmacology. 44(4). 303–306. 90 indexed citations

Dorr, R T, et al.. (1996). Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro. European Journal of Cancer. 32. S21–S25. 32 indexed citations

Petersen, E. A., et al.. (1996). Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. Journal of Antimicrobial Chemotherapy. 38(5). 819–828. 24 indexed citations

Parrish, Alan, R T Dorr, A. Jay Gandolfi, & Klaus Brendel. (1994). Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity. Toxicology in Vitro. 8(6). 1233–1237. 10 indexed citations

Dorr, R T, et al.. (1993). Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.. PubMed. 53(3). 550–6. 23 indexed citations

Hersh, E. M., et al.. (1992). Antiproliferative and Antitumor Activity of the 2-Cyanoaziridine Compound Imexon on Tumor Cell Lines and Fresh Tumor Cells In Vitro. JNCI Journal of the National Cancer Institute. 84(16). 1238–1244. 30 indexed citations

10.

Alberts, David S., Patricia M. Plezia, Denise J. Roe, et al.. (1991). Lack of Ranitidine Effects on Cyclophosphamide Bon Marrow Toxicity or Metabolism: A Placebo-Controlled Clinical Trial. JNCI Journal of the National Cancer Institute. 83(23). 1739–1743. 4 indexed citations

11.

Dorr, R T, et al.. (1991). Biochemical Effects and Toxicity of Mitoxantrone in Cultured Heart Cells. Advances in experimental medicine and biology. 283. 821–825. 3 indexed citations

12.

Bellamy, William, William S. Dalton, & R T Dorr. (1990). The Clinical Relevance of Multidrug Resistance. Cancer Investigation. 8(5). 547–562. 46 indexed citations

13.

Dorr, R T. (1990). Antidotes to vesicant chemotherapy extravasations. Blood Reviews. 4(1). 41–60. 99 indexed citations

14.

Dorr, R T, et al.. (1989). H2-Antagonists and carmustine. Journal of Cancer Research and Clinical Oncology. 115(1). 41–46. 4 indexed citations

15.

Dorr, R T, et al.. (1988). Phase I-II Trial of Interferon-α _2b by Continuous Subcutaneous Infusion over 28 Days. Journal of Interferon Research. 8(6). 717–725. 12 indexed citations

16.

Dorr, R T & S. Effert. (1987). Possibilities of invasive cardiological diagnosis and therapy in West Germany: A comparison with other European countries and the USA. European Heart Journal. 8(suppl F). 62–66. 2 indexed citations

17.

Gandolfi, A. Jay, et al.. (1987). Cisplatin nephrotoxicity: In vitro studies with precision-cut rabbit renal cortical slices. Toxicology and Applied Pharmacology. 90(3). 501–512. 49 indexed citations

18.

Dorr, R T, James D. Liddil, & Jeffrey M. Trent. (1985). Characterization of a mitomycin C (MMC) resistant L-1210 cell line. Proceedings of the American Association for Cancer Research. 26. 1 indexed citations

19.

Dorr, R T, David S. Alberts, & Alice L. Stone. (1985). Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse.. PubMed. 69(4). 431–7. 29 indexed citations

20.

Dorr, R T, David S. Alberts, & Matthew Woods. (1982). Vinca alkaloid ulceration: experimental mouse model and effects of local antidotes. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 23. 109. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact